Contact information
Research groups
DPhil Supervisor Profile
David Kerr
CBE FMedSci FRCP
Professor of Cancer Medicine
- Consultant Physician
Genetics and Genomics
In collaboration with Dr Rachel Midgley, Oncology Clinical Trials Office, we have conducted a series of international adjuvant trials of chemotherapy for colorectal cancer. In parallel, we have established a biorepository of tissue and constitutional DNA (n=3500) which has allowed us to collaborate with Ian Tomlinson to generate a number of cancer susceptibility SNPs and commercial partners to characterise a prognostic mRNA signature which assists in selection of patients for chemotherapy. We are currently developing biomarkers for the anti-angiogenic agent bevacizumab.
Key publications
-
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.
Journal article
Kerr RS. et al, (2016), Lancet Oncol, 17, 1543 - 1557
Recent publications
-
Oncopolicy and global health diplomacy in times of rising populism.
Journal article
Adomako M. et al, (2020), J Public Health Policy
-
Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019).
Journal article
Ren L. et al, (2020), Eur J Surg Oncol
-
Deep learning for prediction of colorectal cancer outcome: a discovery and validation study.
Journal article
Skrede O-J. et al, (2020), Lancet, 395, 350 - 360
-
Prognostic value of DNA ploidy and automated assessment of stroma fraction in prostate cancer.
Journal article
Ersvaer E. et al, (2019), Int J Cancer
-
A phase Ib/ II trial to assess the safety and efficacy of CXD101 in combination with the PD-1 inhibitor nivolumab in patients with metastatic, previously-treated, microsatellite-stable (MSS) colorectal carcinoma (short title CAROSELL)
Conference paper
Saunders MP. et al, (2019), ANNALS OF ONCOLOGY, 30